Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?

Detalles Bibliográficos
Autores principales: Paulino, Eduardo, de Melo, Andreia Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2020
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593230/
https://www.ncbi.nlm.nih.gov/pubmed/33078600
http://dx.doi.org/10.3802/jgo.2020.31.e95
_version_ 1783601338438909952
author Paulino, Eduardo
de Melo, Andreia Cristina
author_facet Paulino, Eduardo
de Melo, Andreia Cristina
author_sort Paulino, Eduardo
collection PubMed
description
format Online
Article
Text
id pubmed-7593230
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-75932302020-11-03 Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial? Paulino, Eduardo de Melo, Andreia Cristina J Gynecol Oncol Expert Opinion Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2020-09-16 /pmc/articles/PMC7593230/ /pubmed/33078600 http://dx.doi.org/10.3802/jgo.2020.31.e95 Text en Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Expert Opinion
Paulino, Eduardo
de Melo, Andreia Cristina
Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
title Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
title_full Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
title_fullStr Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
title_full_unstemmed Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
title_short Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
title_sort olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the paola-1 trial?
topic Expert Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593230/
https://www.ncbi.nlm.nih.gov/pubmed/33078600
http://dx.doi.org/10.3802/jgo.2020.31.e95
work_keys_str_mv AT paulinoeduardo olaparibandbevacizumabinfrontlinemaintenanceofovariancanceranoverrelianceinunpoweredsubgroupanalysisofthepaola1trial
AT demeloandreiacristina olaparibandbevacizumabinfrontlinemaintenanceofovariancanceranoverrelianceinunpoweredsubgroupanalysisofthepaola1trial

Ejemplares similares